Related Experiment Video

Updated: Jul 18, 2026

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform
06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Pharmacogenetics of target genes across the warfarin pharmacological pathway

Suman Lal1, Srinivasa Rao Jada, Xiaoqiang Xiang

  • 1National Cancer Centre, Laboratory of Clinical Pharmacology, Division of Medical Sciences, Singapore, Singapore.

Clinical Pharmacokinetics
|November 23, 2006
PubMed

Insights

Genetic variations in vitamin K metabolism and warfarin processing influence patient response to this anticoagulant. Understanding these polygenic factors is key to optimizing warfarin dosing and reducing variability in treatment effectiveness.

Area of Science:

  • Pharmacogenomics
  • Clinical Pharmacology
  • Biochemistry

Background:

  • Warfarin is a critical anticoagulant for thromboembolic disorders, but its effectiveness varies significantly between individuals.
  • Warfarin functions by inhibiting vitamin K 2,3-epoxide reductase complex, subunit 1 (VKORC1), a key enzyme in the vitamin K cycle essential for blood coagulation.
  • Inter-individual variability in warfarin response necessitates careful dose titration to ensure therapeutic efficacy and minimize bleeding risks.

Purpose of the Study:

  • To investigate the impact of genetic polymorphisms in genes related to vitamin K metabolism and warfarin processing on warfarin pharmacokinetics and pharmacodynamics.
  • To explore how these genetic variations influence warfarin dose requirements across diverse ethnic populations.
  • To elucidate the causal relationships between polygenic influences and variable warfarin dosing.

Main Methods:

  • Review of recent studies examining polymorphisms in genes such as apolipoprotein E (ApoE), VKORC1, cytochrome P450 2C9 (CYP2C9), and gamma-glutamyl carboxylase (GGCX).
  • Analysis of the influence of these genetic variations on warfarin's pharmacokinetic and pharmacodynamic profiles.
  • Examination of ethnic differences in the prevalence of these polymorphisms and their effect on warfarin response.

Main Results:

  • Polymorphisms in VKORC1, CYP2C9, ApoE, and GGCX significantly affect warfarin pharmacokinetics and pharmacodynamics.
  • These genetic variations contribute to substantial inter-individual differences in warfarin dose requirements.
  • Ethnic background plays a role in the distribution of these polymorphisms, leading to varied responses to warfarin therapy.

Conclusions:

  • Genetic factors, including polymorphisms in VKORC1, CYP2C9, ApoE, and GGCX, are crucial determinants of warfarin response.
  • Understanding these polygenic influences is vital for personalizing warfarin therapy and reducing treatment variability.
  • Optimizing anticoagulant therapy with warfarin can be achieved by considering individual genetic profiles and ethnic background.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...